Delivery Order SPE2DR25D3012-SPE2DR26F4D1G
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order on April 24, 2025, valued at $6,707.89 for the supply of Novolog 100 Unit/mL Flexpen 3mL insulin pens. This competitively awarded, firm fixed-price delivery order is set to be completed by April 25, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award was issued by the Medical Supply Chain division of the Defense Logistics Agency under the federal government's medical procurement...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,976.49 by the Defense Logistics Agency (DLA) on September 26, 2025, for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens. The contract operates under firm fixed-price terms with an ultimate completion date of September 29, 2025, and represents a non-set-aside, competitively awarded procurement. This delivery order is executed as a child contract under...
- AmerisourceBergen Drug Corp was awarded a $2,361.39 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on November 14, 2025, for the supply of NovoLog Penfill 100 Unit/ML 3ML insulin pens. This non-set-aside award is scheduled for completion by November 17, 2025, and will be performed at the company's corporate office in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's critical role as a pharmaceutical supplier to the federal...
- The Defense Logistics Agency awarded a $1,827.81 delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Novolog 100 Unit/ML FlexPen 3ML insulin pens. This is a firm fixed price delivery order with an ultimate completion date of December 2, 2025, and represents a non-competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $2,427.99 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, represents a firm fixed-price delivery under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical supply chains, particularly supporting...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,464.90 to AmerisourceBergen Drug Corp for the supply of Novolog 100 Unit/ML FlexPen 3ML insulin pens. This competitively awarded, firm fixed-price delivery order was issued on November 26, 2025, with an ultimate completion date of November 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency valued at $1,970.02 for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This firm fixed-price contract, awarded on November 25, 2025, with an ultimate completion date of November 26, 2025, represents a competitive award with no set-aside designation. The delivery order is issued under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a $5,279.79 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Novolog 100 Unit/ML FlexPen 3ML insulin pens, with completion expected by September 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be performed at the contractor's corporate office location in...
- The Defense Logistics Agency awarded a $8,744.03 delivery order to AmerisourceBergen Drug Corp on December 4, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price, competitively awarded contract with a completion date of December 5, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's competitive standing as a major...
- SPE2DR25D3012Indefinite Delivery Contract
- SPE2DR25D3012-SPE2DR26F4D1GDelivery Order
AmerisourceBergen Drug Corp has been awarded a delivery order by the Defense Logistics Agency for $2,722.40 to supply Novolog 100 Unit/mL FlexPen 3mL insulin pens. The contract, issued on December 9, 2025, with an ultimate completion date of December 10, 2025, utilizes a firm fixed-price arrangement with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting military and federal healthcare systems. As the prime contractor on the SPE2DX IDC, the company provides a comprehensive range of pharmaceutical products and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities worldwide. The Novolog insulin delivery represents a routine operational need within this broader pharmaceutical support vehicle, which covers specialty medications, brand-name and generic drugs, vaccines, and other medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 12/8/25 |